Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Glulisine in Down Syndrome
NCT02432716Phase 1Completed
- Sponsor
- HealthPartners Institute
- Start
- Apr 2015
- Primary completion
- Oct 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin glulisine in Down syndrome (2 arms), sponsored by HealthPartners Institute. Primary endpoint: Safety Measured by Adverse Events at 1 year. Started Apr 2015; status: completed.
02
Drugs
insulin glulisine
03
Conditions
Down syndrome
Beyond the preview
Go deeper on NCT02432716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02432716.